Galectin Therapeutics Inc. GALT 深 沪
已收盘 10-09 16:00:00 美东时间
3.94
+0.300
+8.24%
华盛通- 最 高3.97
- 今 开3.64
- 成交量 15.65万股
- 最 低 3.64
- 昨 收 3.64
- 总市值 3.97亿
- 52周最高 7.13
- 市盈率 静 --
- 换手率 0.16%
- 52周最低 2.025
- 委 比 49.50%
- 总股本 1.01亿
- 历史最高 19.11
- 量 比 0.64
- 振 幅 9.07%
- 历史最低 0.49
- 每 手 1
- 风险率 1.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Galectin Therapeutics, Inc. announced that its management will present and attend the H.C. Wainwright 28th Annual Global Investment Conference on September 14-16, 2026, in New York. The presentation will occur on September 14 at 11:30 AM ET, with a webcast available. The company focuses on developing therapies targeting galectin proteins, particularly for chronic liver diseases and cancers, with its lead drug belapectin targeting galectin-3. The ...
09-10 12:00
Galectin Therapeutics Q2 EPS $(0.14) Misses $(0.09) Estimate
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.09) by 55.56 percent. This is a 16.67 percent decrease over losses of $(0.12) per share from the same period last year.
08-14 20:13
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
Galectin Therapeutics reported Q2 2026 financial results and updates on its belapectin program targeting MASH cirrhosis and portal hypertension. Key highlights include FDA agreement on Phase 3 trial design, publication of trial results in Hepatology and Gastro Hep Advances, and debt conversion enhancing the balance sheet. The company anticipates submitting the Phase 3 protocol in Q3 2026.
08-14 12:00
argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
argenx reported a strong second quarter with $1.5 billion in global product net sales, up 60% year-over-year and 17% quarter-over-quarter. The company expanded the label for VYVGART and VYVGART Hytrulo to include all gMG serotypes, enhancing patient reach. Key milestones include on-track registrational studies for VYVGART in autoimmune myositis and empasiprubart in MMN, supporting pipeline expansion. argenx also advanced its Vision 2030 strategy,...
07-23 05:00
美股牛股 | SK海力士劲升27%！美股ADR较韩股溢价4成；ATAI升逾14%
华尔街称“存储荒”将持续数年！SK海力士劲升27%，美股ADR较韩股溢价4成；ATAI升逾14%，迷幻药开发公司获政策利好；PRE升逾13%，获10亿美元增长融资>>
07-15 18:56
Goldman Sachs Posts Upbeat Q2 Earnings, Joins SK Hynix, Tower Semiconductor And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday. Shares of Goldman Sachs Group Inc (NYSE:GS) rose sharply following the release of quarterly results. The firm reported earnings of $20.98 per share, well above the analyst consensus estimate of $14.40. Net revenue...
07-15 00:38
Top 3 Health Care Stocks That May Keep You Up At Night In June
As of June 30, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices ...
06-30 20:55
美股大行评级 | 美银上调美光科技目标价从950美元升至1500美元，上调迈威尔科技目标价从240美元升至365美元
今日重点评级关注：摩根士丹利：维持杜邦"标配"评级，目标价从52美元升至156美元；蒙特利尔银行：维持Taysha Gene Therapies"跑赢大市"评级，目标价从10美元升至14美元
06-24 14:08
Galectin暴涨21.79% 这家生物科技公司突破200日阻力位实现逆势上涨
核心事件：生物科技标的半乳糖凝集素（GALT）单日大涨21.79%，本次行情为纯技术面驱动的个股独立行情，无对应公司或板块层面的基本面利好消息刺激，属于投机资金...
06-24 00:36
